Welcome to our dedicated page for Stereotaxis SEC filings (Ticker: STXS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Stereotaxis, Inc. filings document an operating medical-technology company focused on robotic systems and instruments for minimally invasive endovascular intervention. Recent Form 8-K reports record operating and financial results, product and regulatory information included in earnings materials, and material-event disclosures.
The company’s SEC record also includes a definitive proxy statement covering annual-meeting and shareholder voting matters, governance, executive compensation, and director elections. Capital-structure filings describe common stock, shelf registration use, and an at-the-market sales agreement for working capital, research and development, and commercialization of the company’s innovation pipeline.
Stereotaxis, Inc. reported stronger top-line results for the quarter ended June 30, 2025, with total revenue of $8.8 million, up from $4.5 million a year earlier, and $16.3 million for the six months versus $11.4 million in 2024. Growth was driven by higher systems sales ($3.0 million in Q2 2025 versus $0.24 million) and increased disposables, service and accessories revenue. Gross margin improved to $4.6 million in the quarter from $3.3 million a year ago, and operating loss narrowed to $4.0 million from $6.0 million in the prior-year quarter.
Despite improved operating performance, the company remains unprofitable with a six-month net loss of $9.6 million and a cumulative deficit of approximately $571.4 million. Cash and cash equivalents were $6.97 million at June 30, 2025, and operating cash used was $5.5 million for the six months. The company completed an earlier acquisition of Access Point Technologies (APT), recognized related intangible assets and goodwill, recorded a $0.5 million contingent consideration revaluation charge, and disclosed a July 2025 registered offering with initial gross proceeds of $8.5 million and $4.0 million expected at a later closing.